This part of the big picture cannot be too far away IMO.............waiting for this box to be tickedOpportunity for growth
IHL’s takeover of APIRx which was announced last week strengthens its global leadership in the cannabinoid and psychedelic sectors.
It marks possibly the most significant corporate transaction in the medicinal cannabis sector since the takeover of GW Pharmaceuticals (developer of CBD-based Epidiolex) by Jazz Pharmaceuticals for US$7.2B that was first announced in May 2021.
An additional 22 clinical and pre-clinical research and development projects have been transferred to IHL, which it says represents aggregate addressable markets of ~US$400 billion annually.
General discussion, page-15535
-
- There are more pages in this discussion • 4,919 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)